Valuation: Genelux Corporation

Market Cap 127M 112M 103M 96.44M 181M 12.02B 185M 1.24B 479M 5.94B 479M 468M 20.6B P/E 2026 *
-3.5x
P/E 2027 * -3.84x
Enterprise Value 127M 112M 103M 96.44M 181M 12.02B 185M 1.24B 479M 5.94B 479M 468M 20.6B EV / Sales 2026 *
-
EV / Sales 2027 * 10.5x
Free-Float
86.02%
Yield 2026 *
-
Yield 2027 * -
1 day-1.03%
1 week-3.20%
Current month-5.90%
1 month-6.51%
3 months+15.73%
6 months-34.32%
Current year-34.17%
1 week 2.79
Extreme 2.79
2.99
1 month 2.67
Extreme 2.67
3.15
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
35.15
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 2014-05-27
Director of Finance/CFO 42 2025-01-29
Chief Tech/Sci/R&D Officer 52 2026-01-01
Director TitleAgeSince
Director/Board Member 68 2002-08-31
Chairman 73 2013-12-31
Chairman 67 2023-03-31
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Chief Technology Officer

174,841 0.3899%
06-15Free

Director

59,975 0.1338%
06-15Free

Director

59,975 0.1338%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-3.20%-4.01%-90.82% 127M
-0.51%-1.96%+66.11%+120.51% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.78%+14.77%+37.54%-1.86% 17.32B
+0.21%+3.20%+29.92%-32.60% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+4.21%+11.01%+33.13% - 12.43B
Average +1.03%+3.98%+39.13%+105.92% 22.64B
Weighted average by Cap. +0.84%+5.13%+49.83%+121.93%

Financials

2026 *2027 *
Net sales - 12.18M 10.68M 9.85M 9.22M 17.28M 1.15B 17.64M 118M 45.79M 568M 45.74M 44.74M 1.97B
Net income -37.1M -32.53M -29.98M -28.07M -52.64M -3.5B -53.73M -360M -139M -1.73B -139M -136M -6B -37.87M -33.2M -30.6M -28.65M -53.73M -3.57B -54.84M -368M -142M -1.77B -142M -139M -6.12B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
26-06-26 US$2.870 -1.03% 353,836
26-06-25 US$2.900 +1.75% 163,778
26-06-24 US$2.850 -2.40% 172,449
26-06-23 US$2.920 0.00% 91,816
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.870USD
Average target price
17.50USD
Spread / Average Target
+509.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock